Eli Lilly to Acquire AtiVecley for Up to $3.8 Billion
Eli Lilly has entered into a definitive agreement to acquire Athira Pharma (referenced in reports as Athira/Ataybekli) for approximately $3.8 billion. This strategic acquisition aims to bolster Lilly’s neuroscience pipeline, ... Read More